Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

A user shared their hormone levels to gauge if they can use finasteride for hair loss without issues. Their hormone levels are mostly within the reference ranges.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

Serum DHT levels and their variations when using dutasteride for hair loss treatment.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A "mature hairline" is subjective and may not indicate future stability. Finasteride and minoxidil are suggested treatments for hair loss.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A 30-year-old male is experiencing hair loss and is concerned about his receding hairline, seeking advice on his Norwood scale classification. He is apprehensive about using Minoxidil and finasteride as treatments.

The user is considering starting finasteride for hair loss but is concerned about potential side effects due to their estradiol levels being near the upper limit. They have consulted a doctor who confirmed their levels are okay to start the treatment.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

Selecting a hair transplant clinic requires avoiding pitfalls like prioritizing quantity over quality and aggressive sales tactics. Ensure the clinic uses experienced surgeons and recommends treatments like minoxidil and finasteride before a transplant.

The conversation is about determining the Norwood level of hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

An 18-year-old with Norwood 2 hair loss is considering finasteride treatment. Bloodwork shows testosterone and hormone levels mostly within normal ranges, except for low estradiol.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

A 23-year-old with hair loss uses finasteride, minoxidil, and other treatments, considering adding dutasteride due to hairline recession. They seek advice on dutasteride's effectiveness and sourcing.

A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.